Norfloxacin (MK-0366) treatment of urinary tract infections in hospitalized patients.

Abstract

Norfloxacin (MK-0366) is a new antibacterial agent, closely related to nalidixic acid, with broad spectrum activity against Gram-positive and Gram-negative organisms, including Pseudomonas aeruginosa. A clinical study was conducted on forty hospitalized patients with bacteriologically proven urinary tract infections; 20 patients were given norfloxacin and 20 co-trimoxazole. Clinical results were excellent in both groups; norfloxacin was effective in infections due to Ps. aeruginosa and other multi-resistant pathogens. No side effects were reported.

• Authors: G Panichi, A Pantosti, G P Testore
• Journal: The Journal of antimicrobial chemotherapy (J Antimicrob Chemother) Vol. 11 Issue 6 Pg. 589-92 (Jun 1983) ISSN: 0305-7453 [Print] England
• PMID: 6224769 (Publication Type: Journal Article)

Chemical References

• Anti-Infective Agents
• Nalidixic Acid
• Norfloxacin

Topics

• Adolescent
• Adult
• Aged
• Anti-Infective Agents (therapeutic use)
• Humans
• Middle Aged
• Nalidixic Acid (adverse effects, analogs & derivatives, therapeutic use)
• Norfloxacin
• Urinary Tract Infections (drug therapy)